Compared to existing clinical and molecular predictors, risk assessment in PPGL has long relied on the following indicators: clinicopathological features (e.g., tumor size, non-adrenal origin, specific secretory phenotype, and Ki-67 index), histopathological scoring systems (such as PASS/GAPP), and certain genetic alterations (including high-risk markers like SDHB inactivation mutations, as well as susceptibility gene mutations in ATRX, TERT promoter, MAML3, VHL, NF1, among others). This evidence concerns the gene SDHB and neoplasm.